SI-BONE, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 08, 2022 at 04:03 pm EDT
Share
SI-BONE, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 25.59 million compared to USD 22.19 million a year ago. Net loss was USD 18.51 million compared to USD 13.98 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.42 a year ago. Diluted loss per share from continuing operations was USD 0.54 compared to USD 0.42 a year ago.
For the six months, sales was USD 48.02 million compared to USD 42.64 million a year ago. Net loss was USD 35.92 million compared to USD 26.22 million a year ago. Basic loss per share from continuing operations was USD 1.06 compared to USD 0.8 a year ago.
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.